Keywords: fda, panel, endorses, wallace, felbatol, laboratories, n-methyl-d-aspartate
FDA PANEL ENDORSES WALLACE'S FELBATOL
Article | 18 January 1993
Wallace Laboratories' N-methyl-D-aspartate receptor antagonist Felbatol (felbamate) has gained the endorsement of a US Food and Drug Administration advisory panel ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
